RTL1000 is an experimental therapy under development by Artielle Immunotherapeutics for treating relapsing-remitting multiple sclerosis (RRMS).

RTL1000 (recombinant T-cell receptor ligand) is a type of molecule that can inhibit the inflammatory activity of T-cells that attack and destroy myelin. In animal models, the therapy was tested on mice with autoimmune encephalomyelitis, which has similar characteristics of MS. The study demonstrated evidence of remyelination and axonal regeneration, which is why researchers believe it could be a viable treatment for repairing damage to the central nervous system in patients with MS.

A Phase 1 (NCT00411723) study on the safety of a single intravenous dose of RTL1000 in people with MS has been completed.

RTL1000 was administered to different dosing groups, each with six participants. Two groups received a single dose of placebo and four groups received a dose of RTL1000. The participants were observed in the hospital during the infusion and for 24 hours afterward. They were followed to evaluate safety parameters every week for 28 days, and then one and two months after treatment.

RTL1000 was found safe.

Artielle is currently planning further studies in MS.

Note: Multiple Sclerosis News Today is strictly a news and information website about the disease. It does not provide medical advice, diagnosis, or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.

 

  1. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3026883/
  2. http://www.artielle.com/pipeline/multiple-sclerosis-trials.php